|Bid||53.00 x 800|
|Ask||56.92 x 3000|
|Day's Range||56.00 - 57.99|
|52 Week Range||50.05 - 94.06|
|Beta (5Y Monthly)||2.53|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Novavax owners have watched their stock crush the market as the share price has run up 112% this year. Novavax, which is still working on a COVID-19 vaccine, rose 2,700% in 2020. Axsome, on the other hand, has no pharmaceuticals to prevent or treat COVID-19 -- it's focused on medicine for depression and migraines.
Biotech companies are about the riskiest investment someone can find in the stock market. For every Amgen, which has gone from a market cap of less than $1 billion 30 years ago to $147 billion today, there are hundreds that fade into obscurity. Each stock has been beaten down but has the potential to inflate shareholders' portfolios if their science proves successful.